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Abstract Previously we have reported that induction of
apoptosis in Jurkat cells results in an inhibition of overall
protein synthesis with the selective and rapid cleavage of
eukaryotic initiation factor (eIF) 4GI. For the cleavage of
eIF4GI, caspase-3 activity is both necessary and sufficient in
vivo, in a process which does not require signaling through the
p38 MAP kinase pathway. We now show that activation of the
Fas/CD95 receptor promotes an early, transient increase in the
level of eIF2K phosphorylation, which is temporally correlated
with the onset of the inhibition of translation. This is associated
with a modest increase in the autophosphorylation of the protein
kinase activated by double-stranded RNA. Using a Jurkat cell
line that is deficient in caspase-8 and resistant to anti-Fas-
induced apoptosis, we show that whilst the cleavage of eIF4GI is
caspase-8-dependent, the enhancement of eIF2K phosphorylation
does not require caspase-8 activity and occurs prior to the
cleavage of eIF4GI. In addition, activation of the Fas/CD95
receptor results in the caspase-8-dependent dephosphorylation
and degradation of p70S6K, the enhanced binding of 4E-BP1 to
eIF4E, and, at later times, the cleavage of eIF2K. These data
suggest that apoptosis impinges upon the activity of several
polypeptides which are central to the regulation of protein
synthesis and that multiple signaling pathways are involved in
vivo. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Fas (Apo-1/CD95) encodes a transmembrane protein be-
longing to the tumour necrosis factor (TNF) receptor family.
Interaction of the receptor with its cognate ligand or cross-
linking with anti-Fas IgM results in rapid programmed cell
death characterised by a series of distinct morphological and
biochemical changes [1^5]. The essential signaling events cou-
pling the Fas/CD95 receptor to apoptosis have been studied
intensively. Numerous proteins have been identi¢ed which
interact with the intracellular domain of Fas/CD95 to assem-
ble the death-inducing signaling complex (DISC). Recruit-
ment of procaspase-8 (FLICE/MACH/Mch5) to the Fas/
CD95 DISC results in its autocatalytic cleavage and activa-
tion [2,3,6], and the inhibition of caspase 8 activity is su⁄cient
to prevent anti-Fas-IgM-induced apoptosis [7]. Downstream
of the DISC, the Fas/CD95 signaling pathway has been
shown to involve additional caspases (e.g. caspases 1, 3, 6^
10), loss of mitochondrial integrity (reviewed in [2,5,6,8]), ac-
tivation of the p38 MAP kinase and JNK stress kinases [9^
12], the inhibition of protein synthesis and the selective cleav-
age of eukaryotic initiation factor (eIF) 4G [12^15]. Activa-
tion of caspase 3, a main downstream executioner in apoptotic
pathways [2^4], is both necessary and su⁄cient for the pro-
teolysis of eIF4G in vivo [16], in a process which does not
require signaling through the p38 MAP kinase pathway [12].
eIF4G, which exists in two isoforms, plays an essential role
in the mechanism of translation by acting as a molecular
bridge between other components of the ribosomal initiation
complex (reviewed in [17^19]). In vivo eIF4G exists partly in
the form of a complex with the mRNA cap-binding protein
eIF4E and the ATP-dependent RNA helicase eIF4A, consti-
tuting the initiation factor eIF4F [18^23]. Within the sequence
of eIF4G there are domains that interact with eIF4E, eIF4A,
eIF3, the poly(A)-binding protein (PABP) and the eIF4E ki-
nase, Mnk1 (reviewed in [18,19]). Interaction of PABP with
eIF4G has been suggested to facilitate the functional associa-
tion of the 3P end of an mRNA with the 5P end [24] and the
association of eIF4G with eIF4E markedly enhances the bind-
ing of the latter to the mRNA cap [25]. The phosphorylation
of eIF4E, which has been correlated with enhanced transla-
tional activity in cells treated with mitogens and growth fac-
tors (reviewed in [19^23]), is facilitated by the binding of the
eIF4E kinase Mnk1 to the C-terminus of eIF4GI [26,27]. The
binding of eIF4E to eIF4G is inhibited by a small family of
proteins, the 4E-BPs, which compete with eIF4G for the cap-
binding factor (reviewed in [19^21]).
Another key initiation factor which can regulate the global
rate of translation in response to physiological insults is eIF2,
which is composed of three subunits (K, L, Q) [22,23,28]. It
forms a ternary complex with initiator Met-tRNAf and gua-
nosine triphosphate (GTP), which then interacts with the 43S
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ribosomal subunit [17]. eIF2 recycling between successive
rounds of initiation can be inhibited by phosphorylation of
the K subunit on Ser-51 by a small family of protein kinases,
which in turn are activated in response to starvation, viral
infection, the induction of apoptosis and cell stress (reviewed
in [28^31]). A well studied eIF2K protein kinase activated by
double-stranded RNA (PKR), which is activated by double-
stranded RNA, is capable of stimulating caspase-dependent
apoptosis in response to bacterial lipopolysaccharide, serum
deprivation and TNF-K. This response is mediated via the
phosphorylation of eIF2K and perhaps also by increases in
the transcription of target genes (reviewed in [28^36]).
Here we demonstrate that activation of the Fas/CD95 re-
ceptor in Jurkat cells results in an early and transient increase
in the phosphorylation of eIF2K and activation of eIF2K ki-
nase activity. Using a cell line that is de¢cient in caspase-8 and
resistant to anti-Fas-induced apoptosis, we show that the
transient increase in the level of eIF2K phosphorylation does
not require caspase-8 activity and occurs prior to detectable
cleavage of eIF4GI. In addition, activation of the Fas/CD95
receptor results in the caspase-8-dependent dephosphorylation
and degradation of p70S6K, the enhanced binding of 4E-BP1
to eIF4E and, at later times, the cleavage of eIF2K. These
data suggest that several proteins which impinge upon the
control of protein synthesis are targets for caspase-dependent
and -independent regulation in vivo during the induction of
apoptosis.
2. Materials and methods
2.1. Chemicals and biochemicals
Materials for tissue culture were from Gibco Life Technologies,
anti-Fas antiserum (clone CH-11) was from Upstate Biotechnology,
antiserum against the cleavage product of poly(ADP-ribose) polymer-
ase (PARP) was from Promega (UK), and that speci¢c for the whole
protein was from Boehringer Mannheim (UK). zVAD.fmk was from
Alexis Corporation, Immobilon polyvinylidine di£uoride (PVDF) was
from Millipore, and microcystin was from Calbiochem (UK). Unless
otherwise stated, all other chemicals were from Sigma.
2.2. Tissue culture
Wild-type human Jurkat T cells and a caspase-8-de¢cient Jurkat
subclone (kindly provided by Dr. J. Blenis, Harvard Medical School,
USA) were grown in RPMI 1640 with Glutamax1, supplemented
with 10% foetal calf serum, as described [10].
2.3. Induction of apoptosis by anti-Fas antiserum
Cells (5U106 cells in 5 ml) were isolated by centrifugation, washed
in ice-cold phosphate-bu¡ered saline (PBS) and resuspended in 1 ml
of RPMI 1640, without serum. Where indicated, cells were incubated
on ice for 30 min with or without 250 ng/ml anti-Fas antiserum [37],
isolated by centrifugation, washed in ice-cold PBS and resuspended in
5 ml of original culture medium for the times indicated in the indi-
vidual ¢gure legends. When used, zVAD.fmk (50 WM) was added to
cultures for 60 min prior to isolation of the cells, and was present in
all subsequent incubations.
2.4. Preparation of cell extracts
Following treatment, cells were isolated in a cooled centrifuge, the
medium removed and cells washed with 1 ml PBS containing 40 mM
L-glycerophosphate and 2 mM benzamidine. Pellets (5U106 cells)
were resuspended in 100 Wl ice-cold Bu¡er A (50 mM (3-[N-morpho-
lino] propanesulfonic acid^KOH, pH 7.2, 2.5 mM ethylene glycol-
bis(L-aminoethyl ether), 1 mM EDTA, 40 mM L-glycerophosphate,
1 WM microcystin, 50 mM NaCl, 7 mM 2-mercaptoethanol, 2 mM
benzamidine, 1 mM phenylmethylsulfonyl £uoride, 2 mM Na3VO4)
and lysed by the addition of 0.5% (by volume) igepal and vortexing.
Cell debris was removed by centrifugation in a microfuge for 5 min at
4‡C and the resultant supernatants frozen in liquid N2.
2.5. Sodium dodecyl sulfate^polyacrylamide gel electrophoresis
(SDS^PAGE) and immunoblotting
Samples containing equal amounts of protein were resolved by
PAGE as described previously [38,39]. Proteins were transferred to
PVDF membrane and visualised by immunoblotting with the antisera
described in individual ¢gure legends, using alkaline-phosphatase-
coupled secondary antibodies. In all cases, detection was within the
linear response of the antiserum to the protein and immunoblots were
quanti¢ed by densitometric scanning.
2.6. Isolation and analysis of eIF4E by 7-methyl GTP
(m7GTP)^Sepharose chromatography
eIF4E and associated proteins were isolated by m7GTP^Sepharose
chromatography and the association of eIF4E with 4E-BP1 was ana-
lysed by Western blotting using speci¢c antisera, as described previ-
ously [40^42].
2.7. Protein kinase assays
Jurkat cell extracts were prepared as described above. Using equal
amounts of protein, p38 MAP kinase activity was assessed by immune
complex assays; the activity of the downstream kinase MAP kinase-
activated kinase-2 was monitored using recombinant hsp25 as sub-
strate, as previously described [41]. Immune complex assays for
p70S6K activity, using rabbit polyclonal antisera to p70S6K (Santa
Cruz) with 40S ribosomes as substrate [43], JNK activity, using
GST-c-jun (1^79) as substrate [42], and immunocomplex autophos-
phorylation of PKR [36,44,45] were performed as previously de-
scribed. All data were quanti¢ed using a Molecular Dynamics phos-
phorimager.
3. Results
3.1. The Fas-induced inhibition of protein synthesis and the
cleavage of eIF4GI are severely attenuated in caspase-8
mutant Jurkat cells
Previously, we have shown that treatment of Jurkat cells
with anti-Fas IgM antiserum resulted in the induction of ap-
optosis, the cleavage of eIF4GI and the inhibition of protein
synthesis within 2 h of treatment [12]. Further studies using
MCF-7 cells have shown that, during apoptosis, caspase-3 is
both necessary and su⁄cient for the cleavage of eIF4GI in
vivo and in vitro [16]. We have now examined the role of
upstream caspases and signaling pathways in mediating the
onset of the inhibition of protein synthesis by comparing a
wild-type Jurkat T cell line, which is sensitive to killing by Fas
antiserum, with a subclone which is resistant to Fas-induced
apoptosis by virtue of a frameshift mutation in the caspase-8
gene [10]. These caspase-8 mutant cells fail to cleave PARP,
caspase-2 or protein kinase C-N in response to activation of
the Fas receptor [10].
To determine whether caspase-8 activity was required for
the long-term, Fas-induced inhibition of protein synthesis [12],
Jurkat cells were treated with anti-Fas antiserum and incu-
bated in the presence of [35S]methionine. Induction of apopto-
sis in the Fas-sensitive, wild-type cells resulted in a pro-
nounced inhibition of protein synthesis, evident within 2 h
of treatment, and a rapid loss of cell viability, as observed
by others [10]. These responses were severely attenuated in the
caspase-8 mutant cells (Fig. 1A) and were also prevented by
preincubation of the wild-type cells with the cell-permeable
caspase inhibitor, zVAD.fmk (data not shown but see Fig.
2). Correspondingly, within 1 h of Fas treatment, the cleavage
of PARP, eIF4GI (Fig. 1B, lanes 1^3), and eIF4GII (data not
shown) was evident in the wild-type cells, but not observed in
the caspase-8 mutant cells (lanes 4^6). Cleavage of eIF4GI
resulted in the appearance of a characteristic immunoreactive
fragment, M-FAG, with an apparent molecular weight of
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76 kDa [12,13,16,46,47]. Under these assay conditions, the
M-FAG species of eIF4GI was stable for approximately 3 h
before it was further processed (data not shown). In the wild-
type cells, and to a lesser extent in the caspase-8 mutant cells,
activation of the Fas receptor results in an early, transient
increase in p38 MAP kinase and JNK kinase activity (Fig.
1C; [10]). More detailed analysis shows that these kinase ac-
tivities peak at 1^2 h after treatment and decline with time
(Fig. 1D). Quanti¢cation of these data indicates that caspase-
8 activity is required for full Fas-mediated activation of the
stress kinases.
To analyse the onset of inhibition of translation more di-
rectly, Jurkat cells were exposed to anti-Fas antiserum for 30
min on ice and then incubated at 37‡C. Rates of protein syn-
thesis at di¡erent times were estimated by measuring
[35S]methionine incorporation over the ¢nal 15 min before
Fig. 1. The Fas-induced inhibition of protein synthesis and the cleavage of eIF4GI are severely attenuated in caspase-8 mutant Jurkat cells.
A: Wild-type (closed squares) or caspase-8-de¢cient (open squares) Jurkat cells (5U106 cells) were isolated by centrifugation and incubated in
the presence of 250 ng/ml anti-Fas antiserum for 30 min, as described in Section 2. Cells were isolated by centrifugation, washed in PBS and
incubated in methionine-free RPMI 1640, in the presence of 10% (by volume) dialysed foetal calf serum and 50 WCi/ml [35S]methionine for the
times indicated. Incorporation of [35S]methionine into protein was determined by TCA precipitation [12,41]. The data are the means þ S.D.
(bars) of three separate experiments, each performed in triplicate. Parallel cultures of wild-type (closed circles) or mutant Jurkat cells (open
circles) were used to determine cell viability, as estimated by trypan blue exclusion. B: Parallel cultures of anti-Fas-treated cells were used to
prepare cell extracts at the times indicated, as described in Section 2. Equal amounts of protein (7.5 Wg) were resolved by SDS^PAGE and the
appearance of the 89 kDa cleavage fragment of PARP (upper panel) and the integrity of eIF4GI (lower panel) were visualised by immunoblot-
ting. The position of the 89 kDa cleavage product of PARP, intact eIF4G and the p76 (M-FAG) cleavage product of eIF4G are indicated.
The results are representative of those obtained in at least 10 experiments. C: Aliquots of extracts (containing 30 Wg protein) prepared from
wild-type (lanes 1^3) or caspase-8 mutant cells (lanes 4^6), incubated with anti-Fas antiserum for 0 h (lanes 1 and 4), 1 h (lanes 2 and 5) or 2 h
(lanes 3 and 6) as described in A, were assayed for p38 MAP kinase (upper panel) or JNK activity (lower panel). The autoradiographs pre-
sented are from a single experiment. D: In vitro kinase assays from three independent experiments, conducted as in C, were quanti¢ed by use
of a phosphorimager and are presented as the means þ S.D. (bars).
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the times indicated in Fig. 2A. Anti-Fas-treatment of wild-
type cells resulted in an 80% decrease in the rate of protein
synthesis between 45 and 60 min of incubation and thereafter,
whereas protein synthesis rates were maintained in mock-
treated cells (open bar). In contrast, incubation of the cas-
pase-8 mutant cells with anti-Fas antiserum resulted in a tran-
sient inhibition of protein synthesis at 45^60 min, followed by
recovery to control rates, an e¡ect not observed in mock-
treated cells (open bar). This biphasic response seen in cas-
pase-8 mutant cells was also exhibited by wild-type cells
treated with the caspase inhibitor, z.VAD.fmk (Fig. 2B, col-
umns 4^6). This agent blocked the severe depression of pro-
tein synthesis rates seen in the wild-type cells after 5 h incu-
bation (Fig. 2B, columns 3 and 6 vs column 1), but only
partially relieved the earlier e¡ect seen at 75 min (columns
2 and 5 vs column 1). These data suggest that the inhibition
of translation rates at early times is, in part, mediated via a
caspase-independent mechanism. In wild-type cells, inhibition
of translation occurred co-incident with the cleavage of PARP
but prior to the detectable cleavage of either eIF4GI (Fig. 2C)
or eIF4GII (data not shown). The transient inhibition of pro-
tein synthesis rates seen in the caspase-8 mutant cells also
occurred in the absence of cleavage of PARP or eIF4GI
(Fig. 2C).
Fig. 2. A transient, caspase-independent inhibition of protein syn-
thesis is observed at early times following anti-Fas treatment of
Jurkat cells which is not associated with the cleavage of eIF4GI.
A: Wild-type cells (left panel) or caspase-8-mutant cells (right panel)
were incubated as in Fig. 1A, except that exposure to
[35S]methionine was for only 15 min prior to harvesting at the times
indicated (these times include the 30 min incubation with anti-Fas
antiserum on ice). Incorporation of [35S]methionine into protein was
measured by TCA precipitation [12,41]. The presented data are the
means þ S.D. (bars) of ¢ve separate experiments; the incorporation
of [35S] methionine into protein for each cell line in the absence of
anti-Fas antiserum (at 75 min incubation) is shown by the open
bars. Similar results were obtained when cells were incubated with
anti-Fas antiserum on ice in the presence of PBS rather than with
RPMI 1640 (data not shown). B: Wild-type cells (columns 1^6) or
caspase-8-mutant cells (columns 7^12) were preincubated for 1 h in
the absence (columns 1^3, 7^9) or presence of 50 WM zVAD.fmk
(columns 4^6, 10^12). Cells were exposed to 250 ng/ml anti-Fas
antiserum as described above, and harvested after 15 min (lanes 1,
4, 7, 10) or incubated for 75 min (lanes 2, 5, 8, 11) or 5 h (lanes 3,
6, 9, 12). [35S]Methionine was added for 15 min prior to harvesting
at the time indicated and incorporation of [35S]methionine into pro-
tein was monitored by TCA precipitation. The presented data are
the means þ S.D. (bars) of three separate experiments, each per-
formed in triplicate. C: Wild-type and caspase-8 mutant cells were
incubated as in A and extracts were prepared at the times indicated.
Equal amounts of protein (7.5 Wg) were resolved by SDS^PAGE
and the integrity of eIF4GI and PARP were visualised by immuno-
blotting. The position of the 89 kDa cleavage product of PARP, in-
tact eIF4GI and the p76 (M-FAG) cleavage product of eIF4GI are
indicated.
6
Fig. 3. The early inhibition of protein synthesis in wild-type Jurkat
cells does not directly correlate with the inactivation of p70S6K or
the increased binding of 4E-BP1 to eIF4E. A: Wild-type and cas-
pase-8 mutant cells were incubated as in Fig. 2A and extracts pre-
pared at the times indicated. Equal amounts of protein (7.5 Wg)
were resolved by SDS^PAGE and the level and phosphorylation
status of p70S6K kinase were visualised by immunoblotting. The po-
sitions of the p85 and p70 forms of S6 kinase are indicated. In the
case of p70S6K kinase, the lower band of the doublet represents the
unphosphorylated form of the enzyme. In addition, eIF4E and asso-
ciated proteins were isolated by m7GTP^Sepharose chromatogra-
phy; the recovery of eIF4E and bound 4E-BP1 was visualised by
immunoblotting, as indicated. Results are from a single experiment
but are representative of those obtained in three separate experi-
ments. B: Cells were incubated in the absence or presence of 50 WM
zVAD.fmk, prior to incubation in the absence or presence of 250
ng/ml anti-Fas antiserum for 75 min. Extracts were prepared and
aliquots (containing 30 Wg protein) prepared from wild-type cells
(left panel) or caspase-8 mutant cells (right panel) were assayed for
p70S6K kinase activity as described in Section 2. The autoradiograph
presented is from a single experiment but is representative of those
obtained on three separate occasions.
FEBS 23925 14-7-00
S.J. Morley et al./FEBS Letters 477 (2000) 229^236232
3.2. Fas induces the inactivation of p70S6K and enhances the
binding of 4E-BP1 to eIF4E
The phosphatidylinositol 3-kinase-regulated pathway has
been shown to have signi¢cant anti-apoptotic signaling prop-
erties [48], and modulates the activity of downstream targets
including the target of rapamycin (mTOR), eIF4E-binding
proteins (4E-BP1/4E-BP2), and p70S6K. Activity of p70S6K is
required for the up-regulation of translation of some speci¢c
mRNAs and for cell cycle progression (reviewed in
[19,21,49,50]). Using wild-type and caspase-8 mutant Jurkat
cells, we have analysed whether such intracellular signaling
events play any role in modulating the Fas-induced inhibition
of translation. Immunoblot analysis of extracts prepared at
di¡erent times after the induction of apoptosis (Fig. 3A)
shows that in the wild-type, but not the caspase-8 mutant
cells, anti-Fas antiserum promoted the dephosphorylation
and destruction of S6 kinase (p70S6K). Immunocomplex ki-
nase assays (Fig. 3B) con¢rmed a decrease in S6 kinase activ-
ity in wild-type cells co-incident with the dephosphorylation
of p70S6K. However, p70S6K activity was retained in the cas-
pase-8 mutant cells and in the wild-type cells preincubated
with zVAD.fmk. To see if increased association of 4E-BP1
with eIF4E coincided with the inhibition of translation at
early times, eIF4E and associated proteins were isolated by
m7GTP^Sepharose chromatography. Immunoblot analysis
showed that whilst the level of eIF4E did not change in either
cell line, there was an increase in the association of 4E-BP1
with eIF4E in wild-type but not caspase-8 mutant cells. This
was only evident from 75 min of incubation (Fig. 3A) and was
prevented by preincubation of wild-type cells with zVAD.fmk
(S. Morley, unpublished data).
3.3. Anti-Fas treatment of both wild-type and caspase-8 mutant
cells results in increased activity of PKR and the
phosphorylation of eIF2K
As the cleavage of eIF4GI and eIF4GII (data not shown),
Fig. 4. The Fas-induced increase in the phosphorylation of eIF2K, but not the cleavage of eIF2K, is independent of caspase-8. A: Aliquots of
extracts (7.5 Wg) prepared from wild-type cells (left panel) or mutant cells (right panel), as described in Fig. 2A, were resolved by SDS^PAGE
and total eIF2K protein or eIF2K in the phosphorylated form were visualised by immunoblotting, as indicated. An immunoreactive, phosphory-
lated cleavage fragment of eIF2K is also visible (wild-type cells, 90 min). Data presented are from a single experiment; results from seven sepa-
rate experiments were quanti¢ed by densitometric scanning and are expressed as the level of eIF2K in the phosphorylated form divided by the
total level of eIF2K (lower panel). Presented data are the means þ S.D. (bars); left panel, *, P6 0.0001; right panel, **, P6 0.0021 (Student’s
paired t-test). B: Wild-type (lanes 1^3) or caspase-8-mutant cells (lanes 4^6) were incubated for 90 min in the absence (lanes 1 and 4) or pres-
ence of anti-Fas antiserum (lanes 2, 3, 5, 6), without (lanes 1, 2, 4, 5) or following pretreatment with z.VAD.fmk (lanes 3 and 6). Extracts pre-
pared as described in A were resolved by SDS^PAGE and the amount of eIF2K in the phosphorylated form was visualised by immunoblotting;
the cleavage fragment of eIF2K (lane 2) is indicated. C: Wild-type (lanes 1^3) or caspase-8-mutant cells (lanes 4^6) were incubated for 60 min
in the absence (lanes 1 and 4) or presence of anti-Fas antiserum (lanes 2, 3, 5, 6), without (lanes 1, 2, 4, 5) or following pretreatment with
zVAD.fmk (lanes 3 and 6). Extracts were prepared and aliquots containing equal amounts of protein were resolved by SDS^PAGE; the
amount of eIF2K in the phosphorylated form was visualised by immunoblotting (upper panel). In addition, eIF2K kinase activity was moni-
tored by incubation of extracts with recombinant eIF2K and [Q32P]ATP for 10 min; the resulting autoradiograph is presented (lower panel).
The data are from a single experiment but are representative of those obtained on ¢ve separate occasions. D: Wild-type (lanes 1^3) or caspase-
8-mutant cells (lanes 4^6) were incubated for the times indicated in the absence (lanes 1 and 4) or presence of anti-Fas antiserum (lanes 2, 3, 5,
6). Extracts were prepared and PKR activity was visualised by immunoprecipitation and an immunocomplex autophosphorylation assay. The
data are from a single experiment but are representative of those obtained on six separate occasions. E: Wild-type (¢lled bars) or caspase-8-mu-
tant cells (open bars) were incubated without or with anti-Fas antiserum for the times indicated in the absence or presence of zVAD.fmk, as in-
dicated. Extracts were prepared and PKR autophosphorylation was measured as in D; presented data are the means þ S.D. (bars) of ¢ve sepa-
rate experiments.
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the inactivation of p70S6K and the increased binding of 4E-
BP1 to eIF4E all appeared to be initiated later than the onset
of the inhibition of translation, we have also analysed the
phosphorylation of eIF2K during induction of apoptosis. In
many cell systems, relatively small changes in the phosphory-
lation of this protein are associated with the inhibition of
global protein synthesis (reviewed in [28,29,31,35,36,51]). Us-
ing antisera which recognise either total eIF2K or eIF2K in the
phosphorylated form, we found that the level of phosphory-
lated eIF2K was signi¢cantly increased in both the wild-type
(Fig. 4A, left panel) and mutant cells (right panel), coincident
with the onset of the inhibition of protein synthesis (Fig. 2A).
However, by 90 min the extent of eIF2K phosphorylation had
returned to the control value in each cell line. At later times,
cleavage of a small proportion of phosphorylated eIF2K was
evident only in the wild-type cells (Fig. 4B, lane 2 vs lane 5)
and this was prevented by preincubation of the cells with
zVAD.fmk prior to exposure to anti-Fas antiserum (lane 3
vs lane 2). It should be noted that whilst the cleavage of
eIF2K was not observed in the caspase-8 mutant cells, phos-
phorylation of eIF2K did occur over a similar time course as
described for the wild-type cells (Fig. 4A).
We have also investigated eIF2K kinase activity during ap-
optosis in Jurkat cells. As shown in Fig. 4C, incubation of
either wild-type (lanes 1^3) or caspase-8 mutant cells (lanes 4^
6) with anti-Fas antiserum resulted in a transient increase in
overall eIF2K kinase activity (lower panel) which corre-
sponded in timing with the increase in eIF2K phosphorylation
(upper panel) and the inhibition of protein synthesis (Fig. 2A).
These events were not prevented by zVAD.fmk in either cell
line indicating that they occur via a caspase-independent
mechanism. We have investigated the possible identity of the
eIF2K kinase involved in these e¡ects. Immunoblotting anal-
ysis of extracts revealed that total PKR levels did not alter
signi¢cantly during the onset of apoptosis in either wild-type
or caspase-8 mutant cell lines (data not shown). As activation
of PKR results in both autophosphorylation and enhanced
kinase activity [28,31,36], we have used immunocomplex au-
tophosphorylation assays to monitor PKR activity during ap-
optosis. Fig. 4D shows that in both wild-type cells and cas-
pase-8 mutant cells, anti-Fas antiserum promoted a moderate,
but reproducible increase in the autophosphorylation of PKR
(quanti¢ed in Fig. 4E). However, similar assays employed to
examine the activity of another eIF2K kinase, PEK [45], in-
dicated that PEK activity was not appreciably increased fol-
lowing anti-Fas treatment of either wild-type or caspase-8
mutant cells (data not shown). As described for the phosphor-
ylation of eIF2K (Fig. 4B), the increase in autophosphoryla-
tion of PKR was una¡ected by pretreatment of either cell line
with z.VAD.fmk (Fig. 4E).
4. Discussion
Cells undergoing apoptosis in response to di¡erent stimuli
display a rapid decrease in the rate of protein synthesis
[12,14,15,52]. Previously, we have described that activation
of the Fas/CD95 receptor in Jurkat and BJAB cells results
in a severe, but incomplete, inhibition of protein synthesis
[12,13], with the selective and rapid cleavage of eIF4GI. In
the present study, we have further examined early events in
apoptosis using two Jurkat T cell lines; wild-type cells which
are sensitive to killing by Fas antiserum and caspase-8 mutant
cells, which are resistant to Fas-induced apoptosis by virtue of
a frameshift mutation in the caspase-8 gene [10]. Our data
indicate that with wild-type cells, activation of the Fas recep-
tor results in a severe decrease in the rate of protein synthesis
between 45 and 60 min of incubation, with translation rates
subsequently maintained at a low level (Fig. 2). In contrast,
although incubation of the caspase-8 mutant cells with anti-
Fas antiserum resulted in a transient inhibition of protein
synthesis, this was followed by recovery to control rates
(Fig. 2). The di¡erential sensitivity of the early and late com-
ponents of this biphasic response to z.VAD.fmk in wild-type
cells suggests that the inhibition of translation rates is medi-
ated via both caspase-independent and -dependent mecha-
nisms, respectively.
In this cell system, the initial inhibition of protein synthesis
cannot be directly attributed to the cleavage of either eIF4GI
(Fig. 2C) or eIF4GII (data not shown), as the transient e¡ect
observed in the caspase-8 mutant cells occurred without
eIF4G cleavage. Furthermore, although anti-Fas antiserum
induced the cleavage of eIF4GI and increased the association
of 4E-BP1 with eIF4E in wild-type cells, these events were not
required for the initial inhibition of protein synthesis (Figs. 2C
and 3A). Similarly, the activation of stress kinases (Fig.
1C,D), the inhibition of p70S6K activity (Fig. 3B), the cleavage
of a proportion of the eIF2K pool (Fig. 4A), and the partial
cleavage of initiation factor eIF4B and the 35 kDa subunit of
eIF3 (data not shown; [46]) all occurred at relatively late
times in Fas-stimulated wild-type cells, subsequent to the in-
hibition of protein synthesis (Fig. 2). Although these data
suggest that none of these events is crucial for the initial in-
hibition of translation, a later role in the apoptotic response,
when the synthesis of selected proteins is maintained [52^55],
remains possible. Indeed, it is well established that both eIF4-
GI and eIF4GII are susceptible to rapid cleavage in picorna-
virus-infected cells, favouring conditions for the IRES-depen-
dent translation of viral mRNAs [56^58]. In addition,
following the cleavage of reticulocyte lysate eIF4G with L
protease in vitro, changes in the translation capacity of the
system can be correlated with the appearance of speci¢c cleav-
age fragments of eIF4G [59,60]. Therefore, in an analogous
manner, the accumulation of the caspase-generated eIF4G
cleavage fragments may directly in£uence mRNA translation
rates in vivo. For example, M-FAG (Fig. 1; [46,47]) may have
a direct role in the translation of speci¢c cellular mRNAs
during apoptosis under conditions where the interaction be-
tween the 5P and 3P ends of the mRNA has been disrupted
(reviewed in [14]). M-FAG, being able to recruit all the nec-
essary factors for basal translation [27,47] and mRNA inter-
action [27,61,62], may still support cap-dependent and/or cap-
independent translation, albeit at a low rate, during apoptosis.
Target mRNAs for M-FAG-mediated recruitment may in-
clude those encoding c-myc [54,63], Apaf-1 [31,53], and
XIAP [52], whose synthesis is maintained in vivo during ap-
optosis. Each of these mRNAs contains an IRES element and
their translation behaviour is reminiscent of the translational
control associated with cellular di¡erentiation [31,64], stress
responses [65], mitosis [66] and starvation responses in yeast
[67]. Moreover, studies have shown that the death-associated
protein 5 (DAP5/p97/NAT1), a member of the eIF4G family
of initiation factors which interacts with eIF3 and eIF4A but
not with eIF4E, is cleaved during apoptosis. This generates a
stable fragment which can maintain the synthesis of DAP5
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itself via a functional IRES element in vitro [55]. Further
work will be required to determine whether such in vivo ef-
fects on speci¢c mRNA translation are directly mediated by
the caspase-generated cleavage fragments of the eIF4G family
of proteins.
One of the earliest e¡ects of apoptotic inducers on Jurkat
cells is an increase in the phosphorylation of eIF2K ; although
this e¡ect is transient, in contrast to the cleavage of eIF4G,
eIF2K phosphorylation correlates with the onset of the inhi-
bition of protein synthesis. In this study, increased phosphor-
ylation of eIF2K could, in part, be ascribed to a modest in-
crease in activation of PKR (Fig. 4D,E), with little or no
e¡ect on the activity of PEK over a similar time course
(data not shown). It has been suggested that PKR may be
acting as a ‘receptor/inducer’ for cell signaling by pro-apopto-
tic agents such as dsRNA, having inputs into the apoptotic
pathways at more than one level [29^31,68,69]. These may
include direct [33,34] or indirect [31,70] e¡ects via both the
phosphorylation of eIF2K and the activity of the DISC-asso-
ciated protein, FADD. In addition to the promotion of DISC
formation [71], signaling through NFUB and p53 may also
play a role in PKR-induced apoptosis [29^31,69,71]. Our
present data suggest that PKR activation or eIF2K phosphor-
ylation are independent of caspase-8 and thus functions up-
stream of this enzyme.
During apoptosis, in addition to becoming more highly
phosphorylated, a population of eIF2K is also cleaved to
give rise to a C-terminally truncated form [46,72,73].
Although it can still be phosphorylated by PKR, the trun-
cated form of eIF2K has been reported to block the PKR-
mediated suppression of reporter gene expression [72], possi-
bly by allowing eIF2B-independent GDP exchange on the
truncated eIF2 complex [73]. Thus the caspase-mediated
cleavage of eIF2K may provide a mechanism for reversing
the e¡ects of phosphorylation on the function of initiation
factor eIF2 during apoptosis. Whether this is responsible for
the recovery of protein synthesis at later times in the caspase-8
mutant cells is not known. However, this recovery was not
inhibited by zVAD.fmk (Fig. 2B).
Alternative possibilities which need to be addressed are that
transient eIF2K phosphorylation may initially promote the
progression of cell death by causing a general inhibition of
protein synthesis, facilitated by the maintained translation of
pro-apoptotic proteins, such as Bax and Fas [2,74,75], or by
impaired synthesis of anti-apoptotic proteins [73]. As Bax and
Fas mRNAs possess upstream open reading frames (uORFs),
and increased synthesis of Bax protein in some cells coincides
with increased levels of eIF2K phosphorylation [71], it is pos-
sible that translational control of Bax mRNA occurs during
apoptosis in a manner similar to that described for GCN4 in
Saccharomyces cerevisiae (reviewed in [29,76]). Further work
is required to resolve these possibilities.
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